| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Radiology, Massachusetts General Hospital, 15 Parkman St., WACC
515, Boston, MA 02114.
2 Department of Radiology, University of California San Francisco, San
Francisco, CA 94143-0628.
3 Department of Nuclear Medicine, VA Palo Alto Health Care System, Palo Alto, CA
94304.
OBJECTIVE. Our objective was to evaluate if whole-body PET with FDG is able to detect bone marrow involvement in patients with multiple myeloma and to assess its appearance and distribution pattern.
MATERIALS AND METHODS. Seventeen whole-body FDG PET scans were performed in 13 patients with multiple myeloma. Four patients were referred for evaluation of extent of disease pretherapy and nine patients were referred for assessment of therapy response (chemotherapy, radiation therapy, bone marrow transplant). FDG PET images were evaluated for distribution and uptake pattern. Standardized uptake values were obtained to quantify FDG uptake. Results of other imaging examinations (MRI, CT, radiography), laboratory data, biopsies, and the clinical course were used for verification of detected lesions.
RESULTS. FDG PET was able to detect medullary involvement of multiple myeloma. There were two false-negative results. In one patient, the radiographic skeletal survey showed subcentimeter lytic lesions within the ribs that were not detected on FDG PET and in the other patient, a lytic lesion detected on radiographs showed only mildly increased FDG uptake that was not identified prospectively. There was one false-positive FDG PET result in a patient who had undergone radiation therapy 3 weeks before PET. FDG PET was helpful in differentiating between posttherapeutic changes and residual/recurrent tumor and in assessing response to therapy. FDG PET resulted in upstaging of disease in four patients, which influenced subsequent management and prognosis. Sensitivity of FDG PET in detecting myelomatous involvement was 85% and specificity was 92%.
CONCLUSION. FDG PET is able to detect bone marrow involvement in patients with multiple myeloma. FDG PET is useful in assessing extent of disease at time of initial diagnosis, contributing to staging that is more accurate. FDG PET is also useful for evaluating therapy response.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M HORGER, P PEREIRA, C D CLAUSSEN, L KANZ, R VONTHEIN, B DENECKE, and C DRIESSEN Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters Br. J. Radiol., May 1, 2008; 81(965): 386 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fonti, B. Salvatore, M. Quarantelli, C. Sirignano, S. Segreto, F. Petruzziello, L. Catalano, R. Liuzzi, B. Rotoli, S. Del Vecchio, et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma J. Nucl. Med., February 1, 2008; 49(2): 195 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ghesani, S. Goel, M. Meka, S. Cohen, A. Chang, and P. Maslin Multiple Myeloma Presenting With [18F]Fluorodeoxyglucose Avid Liver Lesions Diagnosed on Positron Emission Tomography Scan J. Clin. Oncol., November 20, 2007; 25(33): 5319 - 5320. [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Steinbach "MRI in the Detection of Malignant Infiltration of Bone Marrow"--A Commentary Am. J. Roentgenol., June 1, 2007; 188(6): 1443 - 1445. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zamagni, C. Nanni, F. Patriarca, E. Englaro, P. Castellucci, O. Geatti, P. Tosi, P. Tacchetti, D. Cangini, G. Perrone, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma Haematologica, January 1, 2007; 92(1): 50 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dankerl, P. Liebisch, G. Glatting, C. Friesen, N. M. Blumstein, D. Kocot, C. Wendl, D. Bunjes, and S. N. Reske Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience Radiology, December 19, 2006; (2006) 2422051980. [Abstract] [Full Text]
|
|
|
|
 |
|
 M Hoffmann, S Wohrer, A Becherer, A Chott, B Streubel, K Kletter, and M Raderer 18F-Fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference Ann. Onc., December 1, 2006; 17(12): 1761 - 1765. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
